Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorraine A Fitzpatrick

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Menopause (New York, N.Y.)|July 16, 2020
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtendSusan L Greenspan, Lorraine A Fitzpatrick, Bruce Mitlak, et al.
The Journal of Clinical Endocrinology and Metabolism|May 20, 2011
The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral densityLorraine A Fitzpatrick, Christine E Dabrowski, Gregory Cicconetti, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2013
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronateSanjay Kumar, Sandra J Hoffman, Rana Samadfam, et al.
Bone|July 12, 2011
Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trialLorraine A Fitzpatrick, Phillipa L Smith, Trish A McBride, et al.
Bone|June 13, 2013
Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal womenStephen Caltabiano, Colin T Dollery, Mohammad Hossain, et al.
Yonsei Medical Journal|June 29, 2002
An unusual case of osteoblastic metastasis from gastric carcinomaYoon-Sok Chung, Tae-Young Choi, Chang-Young Ha, et al.
Current Medical Research and Opinion|August 17, 2019
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trialJohn P Bilezikian, Gary Hattersley, Bruce H Mitlak, et al.
JBMR Plus|February 22, 2021
Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE StudyRuban Dhaliwal, Didier Hans, Gary Hattersley, et al.
JBMR Plus|April 8, 2020
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE StudyRuban Dhaliwal, Didier Hans, Gary Hattersley, et al.
Endocrine Reviews|August 6, 2004
Molecular, endocrine, and genetic mechanisms of arterial calcificationTerence M Doherty, Lorraine A Fitzpatrick, Daisuke Inoue, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Menopause (New York, N.Y.)|July 16, 2020
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtendSusan L Greenspan, Lorraine A Fitzpatrick, Bruce Mitlak, et al.
The Journal of Clinical Endocrinology and Metabolism|May 20, 2011
The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral densityLorraine A Fitzpatrick, Christine E Dabrowski, Gregory Cicconetti, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2013
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronateSanjay Kumar, Sandra J Hoffman, Rana Samadfam, et al.
Bone|July 12, 2011
Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trialLorraine A Fitzpatrick, Phillipa L Smith, Trish A McBride, et al.
Bone|June 13, 2013
Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal womenStephen Caltabiano, Colin T Dollery, Mohammad Hossain, et al.
Yonsei Medical Journal|June 29, 2002
An unusual case of osteoblastic metastasis from gastric carcinomaYoon-Sok Chung, Tae-Young Choi, Chang-Young Ha, et al.
Current Medical Research and Opinion|August 17, 2019
Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trialJohn P Bilezikian, Gary Hattersley, Bruce H Mitlak, et al.
JBMR Plus|February 22, 2021
Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE StudyRuban Dhaliwal, Didier Hans, Gary Hattersley, et al.
JBMR Plus|April 8, 2020
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE StudyRuban Dhaliwal, Didier Hans, Gary Hattersley, et al.
Endocrine Reviews|August 6, 2004
Molecular, endocrine, and genetic mechanisms of arterial calcificationTerence M Doherty, Lorraine A Fitzpatrick, Daisuke Inoue, et al.
Pageof 7